Heart failure

Q: What is the clinical evidence from this study?

Study design: RCT. Population: Heart failure (HFrEF) (n=4744). Intervention: Dapagliflozin vs. Placebo. Primary outcome: Hospitalizations for heart failure (RR 0.70, 95% CI null, p=null).

John Cleland; Alexander Lyon; T McDonagh; John McMurray

doi:10.5937/siks2002073c

January 1, 2020Srce i krvni sudoviOpen Access

Heart failure

View Full Paper

Ask AI

Bookmark

Share

Key Points

To review recent advances, clinical trial findings, and emerging concepts regarding the epidemiology, prevention, diagnosis, and management of heart failure.
Narrative synthesis of recent clinical trials, epidemiological surveys, and primary care registries evaluating heart failure prevention, diagnosis, and therapies.
Evaluation of diagnostic tools, including natriuretic peptide biomarkers and advanced imaging for haemodynamic and tissue congestion.
Review of age-stratified outcomes and pharmacotherapeutic efficacy across diverse heart failure phenotypes.
Cardiovascular prognosis in new-onset heart failure improved between 2002 and 2014 (HR: 0.73; 95% CI 0.68–0.80), though non-cardiovascular mortality completely offset this survival gain in patients aged >80 years.
Meta-analysis demonstrated that mineralocorticoid receptor antagonists reduced mortality by approximately 25% in patients with reduced ejection fraction both above and below age 75 years.
A long-term follow-up of 4403 bariatric surgery candidates showed that 9% (188 of 2003) of surgical patients developed heart failure versus 13% (266 of 2030) in non-surgical controls over 22 years.

Study Design

Type

RCT (n=4,744)

Blinding

null

Randomization

null

PICO

P

Population

Heart failure (HFrEF) (n=4,744)

I

Intervention / Comparator

Dapagliflozin vs Placebo (null)

O

Primary Outcome

Hospitalizations for heart failure — RR 0.70 (null), p=null

Main Result

Effect estimate: RR 0.70 (95% CI null)

p-value: p=null

This review highlights key developments in heart failure research from the past year, emphasizing earlier diagnosis, the diversity of heart failure phenotypes, and the evolving roles of medical and device therapies.

Ask about this paper

Answers are grounded in this paper and cite their sources.

Implication

May support SGLT2i integration in HFrEF; leaves open optimal sequencing across phenotypes.

Abstract

The article does not contain abstract.

Discussion

No takes yet. Share an insight, caveat, or question.

Cite This Study

Cleland et al. (2020) conducted an RCT in Heart failure (HFrEF) (n=4,744). Dapagliflozin vs. Placebo was evaluated on Hospitalizations for heart failure (RR 0.70, 95% CI null, p=null).

synapsesocial.com/papers/69785538ccb046adae51762f https://doi.org/10.5937/siks2002073c

View Full Paper

Ask AI

Bookmark

Share

Heart failure

Key Points

Study Design

PICO

Main Result

Ask about this paper

Implication

Abstract

Discussion

Cite This Study

Heart failure

Key Points

Study Design

PICO

Main Result

Ask about this paper

Implication

Abstract

Discussion

Cite This Study

Keep reading

Keep reading